about
Interferon-alpha, immune activation and immune dysfunction in treated HIV infectionInsufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cellsHepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus controlInterferon-alpha subtype 11 activates NK cells and enables control of retroviral infectionTetherin/BST-2: Restriction Factor or Immunomodulator?Type I interferon signaling is required for the APOBEC3/Rfv3-dependent neutralizing antibody response but not innate retrovirus restriction.Different antiviral effects of IFNα subtypes in a mouse model of HBV infection.The early interferon alpha subtype response in infant macaques infected orally with SIV.Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypesPD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell KillingIFN-α subtypes: distinct biological activities in anti-viral therapy.Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication.Interferons as biomarkers and effectors: lessons learned from animal models.Efficacy of antiviral chemotherapy for retrovirus-infected cats: What does the current literature tell us?Dose of Retroviral Infection Determines Induction of Antiviral NK Cell Responses.Interferon-α-induced CD100 on naïve CD8+ T cells enhances antiviral responses to hepatitis C infection through CD72 signal transduction.Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.Efficacy of a Virus-Like Nanoparticle As Treatment for a Chronic Viral Infection Is Hindered by IRAK1 Regulation and Antibody Interference.Regulatory T cells in retroviral infections.Distinct antiviral activities of IFN-α subtypes.
P2860
1e0023b44f6e8e7075ca88f49c8d4d626f48434a68ad5c8cf1022f7ddeca1eb60a42c8379d569063872ce29847a771c57e05829dfed6e1ab39449ad5ab77dcd5ba4dc928cd8eea746758d0b9cf81c874c0f7f6ea8bd44e938e0b3d83d689489d62a79342c5b5a264d74bf684fc45cc99b3b2c0479182c5e2d7581eb30b2b2cece3c7fb5ca032df4c7a12ac75f6770a60de09b9d792b2d9b41798ce29292ec0f0
P248
Q26861003-60C1CCDC-18F2-4088-B392-5FB65447C271Q28068375-EBBFC9E3-07AE-47F5-9AE1-BAFCAAB3B9FAQ28082128-0108C120-0EC8-4D76-A0C8-8E46026B8CB1Q28482160-422B4050-AB42-40A3-BE26-973A6721798EQ30385433-631ACD8C-6CC5-4D06-A2D6-00FC603CF3EEQ33568321-AFA9F95F-D517-460C-A14E-992773005FEDQ33671963-43E3ADED-2356-4695-A39E-FE82122836C5Q34082151-8BC68A43-88E9-4EDF-8A66-BADEE3CAFF83Q35353052-6C799CC9-F2D6-4222-8FE0-BB6F72ED5C57Q35814368-298B801F-B345-4949-AD8D-6B484F4E45F0Q36675798-30E013CE-7046-44B6-A2A9-57748D6B34E6Q36730005-C7413D8C-DF91-42F4-A45F-B34A7F2E3F07Q37997045-F33DFA4B-A663-4ED8-B33C-481556F0DAA8Q38612672-6774DB4F-8B5C-4907-B571-C2270BD7F1A9Q40042449-D8BDCC18-722A-454C-B078-FE5EADBD0F4FQ40323617-D2135E4B-FFAA-440A-BB8A-FC93A515F4E5Q40705563-C011E027-D915-4824-A2C8-233D82342DD4Q40709115-9F07DAD0-8BD6-4F76-A7A9-EF2DC27A2165Q44742776-A8B8579E-5074-4FFE-B0CA-C60853E48014Q47550781-0B474F22-BB15-4D4C-B5FC-0F14A68DBB55Q49979151-50624EC5-746E-4851-AA50-BC53EFA80B1BQ54574669-8DA72D38-E2EB-49C2-B970-9B438186E025
P2860
description
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2009
@ast
im Januar 2009 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2009/01/01)
@sk
vědecký článek publikovaný v roce 2009
@cs
wetenschappelijk artikel (gepubliceerd op 2009/01/01)
@nl
наукова стаття, опублікована в січні 2009
@uk
مقالة علمية (نشرت عام 2009)
@ar
name
Anti-retroviral effects of type I IFN subtypes in vivo
@ast
Anti-retroviral effects of type I IFN subtypes in vivo
@en
Anti-retroviral effects of type I IFN subtypes in vivo
@nl
type
label
Anti-retroviral effects of type I IFN subtypes in vivo
@ast
Anti-retroviral effects of type I IFN subtypes in vivo
@en
Anti-retroviral effects of type I IFN subtypes in vivo
@nl
prefLabel
Anti-retroviral effects of type I IFN subtypes in vivo
@ast
Anti-retroviral effects of type I IFN subtypes in vivo
@en
Anti-retroviral effects of type I IFN subtypes in vivo
@nl
P2093
P2860
P921
P3181
P356
P1476
Anti-retroviral effects of type I IFN subtypes in vivo
@en
P2093
Cassandra M. James
Christina Alter
Gennadiy Zelinskyy
Kathrin Gibbert
Nicole Gerlach
Savita Nair
P2860
P304
P3181
P356
10.1002/EJI.200838311
P407
P50
P577
2009-01-01T00:00:00Z